HomeIndustriesHealthcareModerna (MRNA) CFO On Covid Vaccine Demand & Earnings

Moderna (MRNA) CFO On Covid Vaccine Demand & Earnings

Moderna (MRNA) posts a wider loss and cuts guidance as Covid vaccine sales drop. Its adjusted EPS came in at -$9.53 versus an estimated -$2.01 and revenue came in at $1.83B versus an estimated $1.33B. Moderna CFO Jamey Mock joins Oliver Renick to give an overview of the company. He talks about how MRNA sees at least $6B of Covid-19 vaccine sales in 2023. MRNA expects 50M doses in the U.S. this fall, which was previously estimated at 50M-100M doses. Mock then goes over what’s in the pipeline for MRNA. Tune in to find out more about the stock market today.

Market On Close

02 Nov 2023

SHARE

ON AIR
4:30 pm
Market On Close
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Liz Ann Live
REPLAY
1:30 pm
The Wrap
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
ON AIR
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor